Lineage Cell Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Expanded cell therapy pipeline with new programs in ophthalmology and diabetes, robust manufacturing advances, and strong cash position. OpRegen continues to show promise as a disease-modifying treatment, with multiple clinical and partnership milestones anticipated in 2026.
Fiscal Year 2025
-
Key milestones achieved in cell therapy programs, with expanded clinical trials, new research initiatives, and strong financial runway into Q2 2028. Manufacturing scalability and strategic partnerships support pipeline growth and capital efficiency.
-
OpRegen clinical expansion, new partnerships, and manufacturing advances drive momentum, with a strong cash position and extended runway. Key programs in hearing loss and type 1 diabetes progress, while CIRM grant and milestone payments could further boost funding.
-
New initiatives include a type 1 diabetes program targeting manufacturing scale, and a hearing loss partnership with William Demant Invest. Lead therapy for dry AMD shows durable vision gains, while manufacturing advances enable scalable, pure cell production. Strategic partnerships and platform expansion drive future growth.
-
OpRegen continues to show durable vision gains in dry AMD, with strong external validation and partner support. Financials reflect a solid cash runway, increased revenue, and a non-cash impairment, while OPC1 advances with new delivery technology and manufacturing improvements.
-
OpRegen has shown unprecedented vision gains in dry AMD with GA, with durable benefits expected to persist in upcoming three-year data. The Roche partnership brings significant milestones and validates the approach, while Lineage’s manufacturing platform supports expansion into new cell therapy indications.
-
OpRegen continues to show durable benefits in dry AMD, with three-year data upcoming and strong partner support. Manufacturing breakthroughs enable large-scale, low-cost production, opening new partnership opportunities. OPC1 advances in spinal cord injury with improved delivery and manufacturing.
-
Cell therapy is advancing beyond oncology, with a deep pipeline of allogeneic assets targeting neuro and ocular diseases. Lead program OpRegen, partnered with Genentech, shows durable vision improvements in dry AMD. Manufacturing scalability and new delivery systems are key strategic focuses.
Fiscal Year 2024
-
OpRegen continues to show durable clinical benefits in dry AMD, with strong partner engagement and industry validation. Financials improved year-over-year, with a cash runway into Q1 2027 and potential for further funding tied to clinical milestones.
-
Cash runway extended into Q1 2026, with Q3 net loss reduced to $3M and revenue up to $3.8M. OpRegen's phase IIa trial progresses with RMAT designation, while OPC1 and ReSonance advance in development. Manufacturing scale-up and potential milestone payments could further strengthen the outlook.
-
OpRegen, an RPE cell transplant for dry AMD, demonstrated durable vision and retinal structure improvements in clinical trials, with zero rejection cases and minimal immunosuppression. Backed by a $670 million Roche/Genentech partnership, the program is expanding globally and targeting multi-billion dollar markets.
-
Q2 2024 saw reduced revenue and a net loss, but strong fiscal discipline extended the cash runway into Q4 2025. OpRegen's Phase II trial progresses with Roche/Genentech, while OPC1 and ANP1 pipeline programs advance amid cautious biotech market conditions.